65,437 trials
Type 2 Diabetes Mellitus
Primary: Primary Efficacy Outcome MACE Events — 905; 839 Participants — p=0.061
Cancer of Liver
Primary: Patients Survival (Safety) — 12 Participants
Lung Cancer
Primary: Concurrence Between the Telephonic Interview and the Physician Assessment — 0.64 probability
Pain · Low Back Pain · Osteoarthritis
Primary: Change From Baseline in NRS Pain Intensity — -0.24 units on a scale
Melena · Gastrointestinal Hemorrhage
Primary: Time to Localization of Bleeding — 21; 16 hours — p=.002
Anemia
Primary: Percentage of Participants With Hemoglobin Levels Within 10.0 - 12.0 g/dL at Months 8-10 — 51.2 percentage of participants
Acellular Pertussis · Diphtheria · Tetanus
Primary: Number of Seroprotected Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies — 1418; 717; 1439; 728 Participants
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Skin Neoplasms
Primary: Number of Participants With Treatment-emergent Adverse Events Related to Clinical Investigation Product During the 30 Days of Follow-up — 2; 3 Participants
Metastatic Cancer
Primary: Number of Participants With Clinically Significant Adverse Events (AEs) (Physical Assessments and Clinical Lab Tests) — 2; 4; 4; 8 Participants
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of Metformin — 12100; 16800 Nanogram*Hour per Milliliter…
Chronic Pain
Primary: Change in Paresthesia Distribution From Subject Completed Paresthesia Drawing Questionnaire — 13; 0 Participants
Healthy Volunteers
Primary: Urinary and Fecal Excretion of LY2835219-Related Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered — 3.43; 81.0 percentage…
Diabetes Mellitus, Type 1
Primary: Glycemic Response During Exercise and Early Recovery — 86; 85; 174; 161 mg/dL — p=<0.001
Postoperative Pain
Primary: Pain Scores at Rest — 6.7; 6.2 units on a scale